PortViewPortView
Akili logo

Akili (AKLI) Stock Analysis

NASDAQHealthcareMedical - Healthcare Information Services

$0.43+0.25%
1-year price historyRange $0.21 – $1.21
52-week range$0.43
$0.19$1.25

What Akili does

Akili, Inc. is a digital medicine enterprise focused on developing innovative digital therapies for individuals experiencing cognitive impairments. Its flagship product, EndeavorRx, stands out as a unique video game-based treatment that necessitates a physician's prescription and is specifically engineered to directly target and improve cognitive functioning. This company operates from its headquarters in Boston, Massachusetts.

Key metrics

Market cap
$34.10M
P/E (TTM)
-0.71
EPS (TTM)
$-0.61
Beta
1.73
Dividend yield
0.00%
Revenue / share
$0.02
50-day avg
$0.40
200-day avg
$0.38
52-week high
$1.25
52-week low
$0.19
CEO
Matthew Franklin

ETFs linked to AKLI

Broad-market and Healthcare sector ETFs an investor holding Akili is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AKLI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze AKLI in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Akili?
Akili trades under the ticker AKLI on NASDAQ.
Which exchange is AKLI listed on?
AKLI is listed on NASDAQ.
What sector does Akili operate in?
Akili is classified in the Healthcare sector (Medical - Healthcare Information Services industry).
How can PortView help analyze AKLI in a portfolio?
PortView shows AKLI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.